Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple hepatitis attacks in drug addicts.

G Norkrans, G Frösner, S Hermodsson

    JAMA
    |March 14, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activated Cellular Immunity in Chronic Hepatitis C.

    Hematology (Amsterdam, Netherlands)·2016
    Same author

    Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

    Alimentary pharmacology & therapeutics·2015
    Same author

    Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

    Journal of viral hepatitis·2013
    Same author

    Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.

    Journal of viral hepatitis·2013
    Same author

    Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2011
    Same author

    IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

    Journal of viral hepatitis·2011
    Same journal

    WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

    JAMA·2026
    Same journal

    FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

    JAMA·2026
    Same journal

    HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

    JAMA·2026
    Same journal

    US Dietary Supplement Use Increasing, Especially in Older Adults.

    JAMA·2026
    Same journal

    Heat Stress From Climate Change Surges Globally.

    JAMA·2026
    Same journal

    Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

    JAMA·2026
    See all related articles

    Hepatitis A and B were common in drug addicts with recurrent hepatitis. Hepatitis non-A, non-B was frequent in initial attacks but not third attacks, with lower liver enzyme levels and less chronic disease development.

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Drug addicts are a high-risk group for viral hepatitis.
    • Multiple hepatitis episodes in this population warrant etiological investigation.

    Purpose of the Study:

    • To serologically identify causative agents of hepatitis in drug addicts with multiple attacks.
    • To differentiate between hepatitis A, hepatitis B, and non-A, non-B hepatitis in this cohort.

    Main Methods:

    • Radioimmunoassays were employed to detect hepatitis B surface antigen (HBsAg), antibodies to HBsAg (anti-HBs), antibodies to hepatitis B core antigen (anti-HBc), and antibodies to hepatitis A virus (anti-HAV) including IgM class.
    • Serological exclusion was used to classify non-A, non-B hepatitis, considering Epstein-Barr virus and cytomegalovirus infections.

    Related Experiment Videos

    Main Results:

    • Hepatitis A accounted for 32% and hepatitis B for 42% of 71 hepatitis episodes.
    • Hepatitis non-A, non-B represented 25% of episodes and was more common in primary attacks (39%) than subsequent ones.
    • Hepatitis non-A, non-B showed lower peak alanine aminotransferase and bilirubin levels compared to hepatitis B and had a lower rate of chronic liver disease development (7%).

    Conclusions:

    • Hepatitis A and B are significant causes of recurrent hepatitis in drug addicts.
    • Hepatitis non-A, non-B is a distinct entity in this population, with a different clinical course and lower risk of chronicity.
    • Understanding the etiology of hepatitis in drug users is crucial for management and prevention strategies.